Activity Preview

Live

AJP CME: April 2019 - Psychiatric Comorbidity in Moyamoya Disease and Preliminary Guidelines For Treatment

Activity Type:

  • Journal CME


Release Date: 4/1/2019

Expiration Date: 3/31/2021

  • AMA PRA Category 1: 1
  • Participation: 1

Access Activity

Overview

Abstract: Moyamoya disease is a cerebrovascular disorder of unknown etiology characterized by progressive unilateral or bilateral stenosis of the distal internal carotid arteries, frequently extending to the anterior and middle cerebral arteries. Cerebral angiogram reveals fragile compensatory collateral vessels forming along the base of the brain, resembling a diagnostic “puff of smoke”—moyamoya in Japanese. The prevalence of moyamoya is highest in Korea, Japan, and China, although awareness of the disease has resulted in its increased characterization in other countries. In Japan, the incidence rate is estimated at 0.54 per 100,000 individuals, with a female-to-male ratio of 1.98. Illness onset follows a bimodal distribution with a large peak centered at approximately age 5 and a smaller peak at age 40. A family history of the disease is present in up to 15% of identified patients, and in this group the mean age at symptomatic onset is lower than in sporadic cases of moyamoya disease, indicating genetic anticipation. Moyamoya disease may also occur secondary to atherosclerosis, autoimmune illness, neoplasms, Down’s syndrome, or irradiation, among other conditions, referred to as moyamoya syndrome.

Pricing

This activity is only available to AJP CME subscribers.

Don't have a subscription to AJP CME? Subscribe Now! 

  • AJP Subscriber – 12 Month CME Subscription: $155.00
  • Non AJP Subscriber – 12 Month CME Subscription: $310.00

If you have questions about AJP CME subscriptions, please contact appi@psych.org.

Educational Objective

The participant will formulate a recognition of symptoms of moyamoya disease in psychiatric patients as well as an approach to treatment.

Target Audience

This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.

Estimated Time to Complete

Duration: 1 hour
Begin Date: April 1, 2019
End Date: March 31, 2021

How to Earn Credit

In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the quiz and submit your evaluation and study hours (up to 1 AMA PRA Category 1 Credit™).  A score of 60% or higher is required to receive credit.

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Title: Psychiatric Comorbidity in Moyamoya Disease and Preliminary Guidelines For Treatment

Authors: Misty Richards, M.S., M.D., Adrienne Grzenda, M.D., Ph.D., Evelyn Nelson, M.D., Michael Gitlin, M.D.

Affiliations: Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (M.R., A.G., E.N., M.G.).

Disclosures: The authors report no financial relationships with commercial interests.

Discussion of unapproved or investigational use of products*: No.

*APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.

Program Planners

Ned H. Kalin, M.D. (Editor-in-Chief, AJP); Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor, AJP); Michael D. Roy (Editorial Director, AJP); Michael A. Pogachar (Online Content Manager, Journals).  Dr. Kalin has served as a consultant to the Board of Scientific Advisors, the Pritzker Neuropsychiatric Disorders Research Consortium, and the Skyland Trail Advisory Board and as Councilor, Society of Biological Psychiatry. Dr. Rodriguez has served as a consultant to Allergan, Blackthorn, Epiodyne, and Rugen. Mr. Roy and Mr. Pogachar report no financial relationships with commercial interests.

Hardware/Software Requirements

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.
 
Optimal System Configuration:
  • Flash Player: Adobe Flash Player 10.1+ 
  • Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+ 
  • Operating System: Windows XP+ or Mac OS X 10.4+ 
  • Internet Connection: 1 Mbps or higher
  • Screen Resolution: 1024 x 768 pixels.

Minimum Requirements:

  • Windows PC:500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
  • Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

For assistance: Contact educme@psych.org for questions about this course  |  Contact learningcenter@psych.org for technical assistance

Access Activity